Alnylam Pharmaceuticals (ALNY) P/S ratio
Alnylam Pharmaceuticals (ALNY) trades at 5.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 14.4×. That is 7.9% higher than the 13.4× of fiscal 2024. Figures as of 18 Nov 2026, 09:08 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/S ratio today
- 5.7×
- P/S ratio, fiscal 2025
- 14.4×
- Change on fiscal 2024
- +7.9%
- Highest on record
- 57.3×fiscal 2019
- Lowest on record
- 13.1×fiscal 2023
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Alnylam Pharmaceuticals P/S ratio, in more detail
Today's figure is 60.6% below the fiscal 2025 year-end.
Across the 7 fiscal year-ends on record (2019–2025), the highest was 57.3× in fiscal 2019 and the lowest 13.1× in fiscal 2023. Today's P/S ratio is at or below every one of the 7 fiscal year-ends on record; their median is 23.8×.
P/S ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Alnylam Pharmaceuticals P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| Today | 5.7× | — | $156.50 | — | |
| 2025 | 14.4× | 7.9% up | $397.65 | $27.58 | |
| 2024 | 13.4× | 2.2% up | $235.31 | $17.61 | |
| 2023 | 13.1× | 53.1% down | $191.41 | $14.64 | |
| 2022 | 27.9× | 17.2% up | $237.65 | $8.53 | |
| 2021 | 23.8× | 21.5% down | $169.58 | $7.13 | |
| 2020 | 30.3× | 47.0% down | $129.97 | $4.29 | |
| 2019 | 57.3× | — | $115.17 | $2.01 | |
| 2018 | — | — | $72.91 | — | |
| 2017 | — | — | $127.05 | — | |
| 2016 | — | — | $37.44 | — | |
| 2015 | — | — | $94.14 | — | |
| 2014 | — | — | $97.00 | — | |
| 2013 | — | — | $64.30 | — | |
| 2012 | — | — | $18.25 | — | |
| 2011 | — | — | $8.15 | — | |
| 2010 | — | — | $9.86 | — | |
| 2009 | — | — | $17.62 | — | |
| 2008 | — | — | $24.73 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
P/S ratio at health care companies of similar size
| Company | P/S ratio |
|---|---|
| Tenet Healthcare THC | 1.1× |
| Guardant Health GH | 19.7× |
| Alnylam Pharmaceuticals ALNY | 5.6× |
| Zimmer Biomet Holdings ZBH | 2.3× |
| Medpace Holdings MEDP | 7.2× |
Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.
Alnylam Pharmaceuticals, figure by figure
- Alnylam Pharmaceuticals market cap
- Alnylam Pharmaceuticals revenue
- Alnylam Pharmaceuticals earnings
- Alnylam Pharmaceuticals earnings per share (EPS)
- Alnylam Pharmaceuticals P/E ratio
- Alnylam Pharmaceuticals P/B ratio
- Alnylam Pharmaceuticals free cash flow
- Alnylam Pharmaceuticals operating margin
- Alnylam Pharmaceuticals dividend
- Alnylam Pharmaceuticals shares outstanding
- Alnylam Pharmaceuticals total debt
- Alnylam Pharmaceuticals cash on hand
- Alnylam Pharmaceuticals total assets
- Alnylam Pharmaceuticals return on equity (ROE)
- Alnylam Pharmaceuticals return on invested capital (ROIC)
Alnylam Pharmaceuticals (ALNY) overview: price, valuation and scorecardAll health care companies by market value
Alnylam Pharmaceuticals P/S ratio: questions and answers
What is Alnylam Pharmaceuticals's P/S ratio?
Alnylam Pharmaceuticals (ALNY) trades at 5.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 14.4×. That is 7.9% higher than the 13.4× of fiscal 2024.
Is Alnylam Pharmaceuticals's P/S ratio high or low compared with its own history?
Today's P/S ratio is at or below every one of the 7 fiscal year-ends on record; their median is 23.8×.
What are the highest and lowest P/S ratio figures on record for Alnylam Pharmaceuticals?
Across the 7 fiscal year-ends on record (2019–2025), the highest was 57.3× in fiscal 2019 and the lowest 13.1× in fiscal 2023.
How is Alnylam Pharmaceuticals's P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Alnylam Pharmaceuticals it is on record here for 7 fiscal years, 2019 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Alnylam Pharmaceuticals (ALNY) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/ALNY/ps-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.